This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Kimberly A. Workowski, MD
Emory University Atlanta, Ga

Raymond B. Johnson, MD
Pfizer Central Research Groton, Conn

Michael Verdon, PA; Walter E. Stamm, MD
University of Washington Seattle

JAMA. 1993;270(16):1934-1935.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—A single 1-g dose of azithromycin has recently demonstrated effectiveness in treating uncomplicated genital chlamydial infection.¹ As such, azithromycin represents a major advance in the treatment of chlamydial infection and may improve our efforts to limit the spread of this important pathogen. In view of the proven efficacy of the 1-g regimen, we examined whether a lower dose (500 mg) might be as effective in treating chlamydial infection. A lower dose would cost less and might be associated with fewer side effects. Since the mean tissue concentration after a 500-mg dose of azithromycin ranges between 1 and 9 mg/kg, with levels remaining above 1 mg/kg for 2 to 3 days,² the expected tissue levels exceed the 90% minimum inhibitory concentration of Chlamydia trachomatis (0.25 mg/L) for at least several days.³

Eleven men with nongonococcal urethritis, characterized by urethral discharge, microscopic leukocytosis, and positive rapid . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?